drugset / Trial / NCT01616524
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine if 24 weeks of treatment with Pegylated Interferon Lambda plus Ribavirin and 12 weeks of treatment with Pegylated Interferon Lambda plus Ribavirin and Daclatasvir will be safe and effective for treatment of hepatitis C compared to 24 weeks of treatment with Pegylated Interferon Alfa-2a plus Ribavirin
Timeline
- Start
- 2012-07
- Primary completion
- 2014-06
- Completion
- 2014-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daclatasvir | Small molecule | 60 mg | Oral |
| Subject | Pegylated interferon alfa-2a (PegIFNα-2a) | Unknown | 180 ug | Subcutaneous |
| Subject | Pegylated interferon lambda (pegIFNλ) | Unknown | 180 ug | Subcutaneous |
| Background | Ribavirin | Small molecule | 400 mg | Oral |